This article was originally published in The Rose Sheet
Fragrance division revenues advanced 3.3% in local currencies, or 2.8% in Swiss francs, to $664.3 mil. (CHF1=$.78) for the nine month period, flavors and fragrances company announces. Despite a number of new launches, particularly in North America, fine fragrances business continued to perform below last year's level, firm notes. Consumer products sales within the fragrance division outperformed the market, with double-digit growth in North America, although fragrance ingredient sales were below the prior year level. Givaudan net sales during the period were up 1.6% in local currencies, or 1% in Swiss francs, to $1.63 bil., firm adds...
You may also be interested in...
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.